DE69930552D1 - Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen - Google Patents

Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen

Info

Publication number
DE69930552D1
DE69930552D1 DE69930552T DE69930552T DE69930552D1 DE 69930552 D1 DE69930552 D1 DE 69930552D1 DE 69930552 T DE69930552 T DE 69930552T DE 69930552 T DE69930552 T DE 69930552T DE 69930552 D1 DE69930552 D1 DE 69930552D1
Authority
DE
Germany
Prior art keywords
exo
mecamylamine
pharmaceutically acceptable
disorder
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930552T
Other languages
English (en)
Other versions
DE69930552T2 (de
Inventor
Douglas Shytle
Paul Sanberg
Mary Newman
Archie Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Application granted granted Critical
Publication of DE69930552D1 publication Critical patent/DE69930552D1/de
Publication of DE69930552T2 publication Critical patent/DE69930552T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69930552T 1998-12-16 1999-12-16 Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen Expired - Lifetime DE69930552T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11253498P 1998-12-16 1998-12-16
US112534P 1998-12-16
PCT/US1999/030153 WO2000035279A1 (en) 1998-12-16 1999-12-16 Exo-s-mecamylamine formulation and use in treatment

Publications (2)

Publication Number Publication Date
DE69930552D1 true DE69930552D1 (de) 2006-05-11
DE69930552T2 DE69930552T2 (de) 2006-11-30

Family

ID=22344414

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69930552T Expired - Lifetime DE69930552T2 (de) 1998-12-16 1999-12-16 Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
DE69939498T Expired - Lifetime DE69939498D1 (de) 1998-12-16 1999-12-16 Exo-S-Mecamylamin-Formulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69939498T Expired - Lifetime DE69939498D1 (de) 1998-12-16 1999-12-16 Exo-S-Mecamylamin-Formulierung

Country Status (12)

Country Link
US (1) US20020016370A1 (de)
EP (3) EP1139743B1 (de)
JP (5) JP2002532392A (de)
AT (2) ATE320711T1 (de)
AU (2) AU2368600A (de)
CA (2) CA2393437C (de)
CY (1) CY1108577T1 (de)
DE (2) DE69930552T2 (de)
DK (2) DK1634498T3 (de)
ES (2) ES2260959T3 (de)
PT (2) PT1634498E (de)
WO (2) WO2000035279A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
US20070224284A1 (en) * 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
EP2086541A4 (de) * 2006-10-09 2011-06-22 Glaxosmithkline Llc Zusammensetzungen zur reduzierung von nikotinentzugssymptomen und/oder tabakverbrauch
US20080242951A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20090119154A1 (en) * 2007-11-07 2009-05-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content
US20080242952A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Effective response protocols for health monitoring or the like
US20090018407A1 (en) * 2007-03-30 2009-01-15 Searete Llc, A Limited Corporation Of The State Of Delaware Computational user-health testing
US20080242949A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080243005A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080319276A1 (en) * 2007-03-30 2008-12-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090005654A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242948A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20080242947A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Configuring software for effective health monitoring or the like
US20090005653A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
JP2010523587A (ja) * 2007-04-02 2010-07-15 パーキンソンズ インスティテュート 治療処置の副作用の低減のための方法および組成物
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
KR20120048611A (ko) * 2009-07-14 2012-05-15 타가셉트 인코포레이티드 치료를 위한 엑소－ｓ－메카밀아민 방법, 용도, 및 화합물
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
US8809397B2 (en) 2010-05-27 2014-08-19 Targacept, Inc. Nicotinic receptor non-competitive antagonists
AT510837B1 (de) 2011-07-27 2012-07-15 Helmut Dr Buchberger Inhalatorkomponente
JP5681819B2 (ja) 2011-02-11 2015-03-11 バットマーク・リミテッド 吸入器コンポーネント
EP2729148A4 (de) 2011-07-06 2015-04-22 Parkinson S Inst Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson
KR102309513B1 (ko) 2011-09-06 2021-10-05 니코벤처스 트레이딩 리미티드 가열식 흡연가능 재료
KR102433286B1 (ko) 2011-09-06 2022-08-16 니코벤처스 트레이딩 리미티드 가열식 끽연 가능 물질
AT511344B1 (de) 2011-10-21 2012-11-15 Helmut Dr Buchberger Inhalatorkomponente
US8901177B2 (en) * 2012-03-23 2014-12-02 Targacept, Inc. Method of treating bladder disorders
GB201207039D0 (en) 2012-04-23 2012-06-06 British American Tobacco Co Heating smokeable material
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB2513637A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2513639A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2514893B (en) 2013-06-04 2017-12-06 Nicoventures Holdings Ltd Container
GB201407426D0 (en) 2014-04-28 2014-06-11 Batmark Ltd Aerosol forming component
GB2528673B (en) 2014-07-25 2020-07-01 Nicoventures Holdings Ltd Aerosol provision system
WO2016028985A2 (en) * 2014-08-22 2016-02-25 Targacept, Inc. Method for treating hyperhidrosis
GB2533135B (en) 2014-12-11 2020-11-11 Nicoventures Holdings Ltd Aerosol provision systems
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
GB201511349D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
MY192211A (en) 2016-04-27 2022-08-08 Nicoventures Trading Ltd Electronic aerosol provision system and vaporizer therefor
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
GB202203728D0 (en) * 2022-03-17 2022-05-04 Univ Oxford Innovation Ltd Treatments and methods for increasing dopamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039801A (en) * 1985-12-20 1991-08-13 The United States Of America As Represented By The Department Of Health & Human Services Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
EP0302595B1 (de) * 1987-07-07 1994-02-02 Beecham Group Plc Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Also Published As

Publication number Publication date
EP1634498B1 (de) 2008-09-03
CY1108577T1 (el) 2014-04-09
EP1634498A2 (de) 2006-03-15
ATE406797T1 (de) 2008-09-15
JP2016065108A (ja) 2016-04-28
CA2393442A1 (en) 2000-06-22
ES2260959T3 (es) 2006-11-01
EP1634498A3 (de) 2006-03-29
DK1634498T3 (da) 2008-12-15
DE69930552T2 (de) 2006-11-30
EP1139743A4 (de) 2003-01-02
AU2368200A (en) 2000-07-03
EP1139743B1 (de) 2006-03-22
PT1139743E (pt) 2006-06-30
AU2368600A (en) 2000-07-03
JP2002532392A (ja) 2002-10-02
EP1139744A1 (de) 2001-10-10
WO2000035279A1 (en) 2000-06-22
DE69939498D1 (de) 2008-10-16
JP2014051528A (ja) 2014-03-20
PT1634498E (pt) 2008-10-28
ATE320711T1 (de) 2006-04-15
JP2002532393A (ja) 2002-10-02
EP1139744A4 (de) 2003-01-02
ES2313187T3 (es) 2009-03-01
EP1139743A1 (de) 2001-10-10
CA2393437C (en) 2009-12-15
WO2000035280A1 (en) 2000-06-22
DK1139743T3 (da) 2006-07-31
JP2011126909A (ja) 2011-06-30
US20020016370A1 (en) 2002-02-07
CA2393437A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
DE69930552D1 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
BR0206559A (pt) Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE253039T1 (de) Beta 2 -adrenergische rezeptor-agonisten
BRPI0506881A (pt) derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo
WO2002043652A3 (en) Anti-proliferative drugs
EP1201241A3 (de) Zusammensetzungen enthaltend Capsaicin oder seine Analogen und Lokalanästhetika
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
Summers et al. THA—a review of the literature and its use in treatment of five overdose patients
TW200607511A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
Szekely et al. Adjunctive treatment in Parkinson's disease: physical therapy and comprehensive group therapy.
SE7910501L (sv) Lekemedel for behandling av det centrala nervsystemet
ATE433959T1 (de) Analoge von kokain
DK1212060T3 (da) Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom
Sun et al. Management of tetanus: a review of 18 cases
JP2003516947A (ja) ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
Mison-Crighel et al. Glutaminase activity and neocortical excitability
Messer et al. Synthesis, biochemical activity and behavioral effects of a series of 1, 4, 5, 6-tetrahydropyrimidines as novel ligands for M1 receptors
EP1404341A1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
Gross Anticholinergic agents as bronchodilators
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
RU2192275C2 (ru) Способ лечения опийной наркомании
Kim et al. A clinical study of Tic-disorder child with insomnia
Shriyan et al. Fatal flower

Legal Events

Date Code Title Description
8364 No opposition during term of opposition